<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04487405</url>
  </required_header>
  <id_info>
    <org_study_id>04-2019</org_study_id>
    <nct_id>NCT04487405</nct_id>
  </id_info>
  <brief_title>A Multivariate Index Assay for Ovarian Cancer Risk Assessment in Women With Adnexal Mass and High-Risk Germline Variants</brief_title>
  <acronym>OVAnex</acronym>
  <official_title>A Multivariate Index Assay for Ovarian Cancer Risk Assessment in Women With Adnexal Mass and High-Risk Germline Variants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aspira Women's Health</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aspira Women's Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this project is to validate the sensitivity, specificity, positive
      predictive value and negative predictive values of the AMRA blood test for assessing risk of
      cancer in women at high risk for ovarian cancer, due to the presence of a symptomatic adnexal
      mass.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 25, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2030</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2030</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>OVAnex</measure>
    <time_frame>12 months</time_frame>
    <description>OVAnex is a multivariate index assay assessing ovarian cancer risk. The Ovanex MIA uses seven biomarkers with a stepwise algorithm to generate a risk score which ranges from 0 to 20.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">4661</enrollment>
  <condition>Adnexal Mass</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <description>Symptomatic with adnexal mass</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <description>Asymptomatic with adnexal mass</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <description>Women with a predisposition in developing ovarian cancer due to a positive, pathogenic variant</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OVAnex</intervention_name>
    <description>OVAnex is a multivarite index assay assessing ovarian cancer risk</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult women with an ovarian adnexal mass, or in follow up due to the presence of BRCA1/2
        and other germline DNA variants.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patient, 18 years of age or older diagnosed with an ovarian adnexal mass, or in
             follow-up due to the presence of BRCA1/2 and other germline DNA variants.

          -  Patient reviewed, understood, and provided the PI with written informed consent to
             allow blood specimen to be used for research and release of medical information.

        Exclusion Criteria:

          -  Patient is less than 18 years of age

          -  Patient is not being treated in the U.S.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jessica Rana</last_name>
    <phone>8606814310</phone>
    <email>jrana@aspirawh.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tatiana Ferreira-Black</last_name>
    <phone>512-800-2885</phone>
    <email>tferreira@aspirawh.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seven Hills Clinical Research Group</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerard Reilly, MD</last_name>
      <email>gpreilly.shcrg@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 10, 2020</study_first_submitted>
  <study_first_submitted_qc>July 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2020</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

